Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) attributable profit rose 25% to 764.8 million yuan in the first quarter from 609.7 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the drug company increased 26% to 0.29 yuan from 0.23 yuanin the year-ago period.
Operating income declined 7.3% to 9.42 billion yuan from 10.2 billion yuan in the prior-year period.
Shares slipped 4% in Hong Kong during afternoon trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。